ULTRAGENYX PHARMACEUTICAL INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $34.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-05
- ULTRAGENYX PHARMACEUTICAL INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $34.00M, a 10.53% decline year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $30.00M, a 23.08% decline year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $36.97M, a 10.05% decline year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $37.20M, a 10.93% decline year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $152.00M, a 4.40% decline from fiscal 2024.
- ULTRAGENYX PHARMACEUTICAL INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $159.00M, a 17.78% increase from fiscal 2023.
- ULTRAGENYX PHARMACEUTICAL INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $135.00M, a 2.50% increase from fiscal 2022.
- ULTRAGENYX PHARMACEUTICAL INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $131.71M, a 25.13% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $34.00M 10-Q · filed 2026-08-05 | $64.00M 10-Q · filed 2026-08-05 | $100.97M derived: sum of 3 quarters · filed 2026-08-05 | $138.16M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2026-03-31 | $30.00M 10-Q · filed 2026-05-06 | $66.97M derived: sum of 2 quarters · filed 2026-05-06 | $104.16M derived: sum of 3 quarters · filed 2026-05-06 | $142.16M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-12-31 | $36.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $74.16M derived: sum of 2 quarters · filed 2026-02-18 | $112.16M derived: sum of 3 quarters · filed 2026-08-05 | $152.00M 10-K · filed 2026-02-18 | |||
| 2025-09-30 | $37.20M 10-Q · filed 2025-11-05 | $75.20M derived: sum of 2 quarters · filed 2026-08-05 | $115.03M 10-Q · filed 2025-11-05 | $155.29M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-06-30 | $38.00M 10-Q · filed 2026-08-05 | $38.27M 10-Q · filed 2025-08-06 | $77.00M 10-Q · filed 2026-08-05 | $77.84M 10-Q · filed 2025-08-06 | $118.09M derived: sum of 3 quarters · filed 2026-08-05 | $159.85M derived: sum of 4 quarters · filed 2026-08-05 | |
| 2025-03-31 | $39.00M 10-Q · filed 2026-05-06 | $39.57M 10-Q · filed 2025-05-07 | $80.09M derived: sum of 2 quarters · filed 2026-05-06 | $121.85M derived: sum of 3 quarters · filed 2026-05-06 | $161.33M derived: sum of 4 quarters · filed 2026-05-06 | ||
| 2024-12-31 | $41.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $82.85M derived: sum of 2 quarters · filed 2026-02-18 | $122.33M derived: sum of 3 quarters · filed 2026-02-18 | $159.00M 10-K · filed 2026-02-18 | $158.12M 10-K · filed 2025-02-19 | ||
| 2024-09-30 | $41.76M 10-Q · filed 2025-11-05 | $81.24M derived: sum of 2 quarters · filed 2025-11-05 | $117.91M 10-Q · filed 2025-11-05 | $152.13M derived: sum of 4 quarters · filed 2026-02-18 | |||
| 2024-06-30 | $39.48M 10-Q · filed 2025-08-06 | $76.15M 10-Q · filed 2025-08-06 | $110.37M derived: sum of 3 quarters · filed 2026-02-18 | $146.61M derived: sum of 4 quarters · filed 2026-02-18 | |||
| 2024-03-31 | $36.67M 10-Q · filed 2025-05-07 | $70.89M derived: sum of 2 quarters · filed 2026-02-18 | $107.14M derived: sum of 3 quarters · filed 2026-02-18 | $141.57M derived: sum of 4 quarters · filed 2026-02-18 | |||
| 2023-12-31 | $34.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $70.47M derived: sum of 2 quarters · filed 2026-02-18 | $104.90M derived: sum of 3 quarters · filed 2026-02-18 | $135.00M 10-K · filed 2026-02-18 | $134.17M 10-K · filed 2024-02-21 | ||
| 2023-09-30 | $36.24M 10-Q · filed 2024-11-06 | $70.68M derived: sum of 2 quarters · filed 2024-11-06 | $100.78M 10-Q · filed 2024-11-06 | $130.63M derived: sum of 4 quarters · filed 2025-02-19 | |||
| 2023-06-30 | $34.43M 10-Q · filed 2024-08-02 | $64.53M 10-Q · filed 2024-08-02 | $94.38M derived: sum of 3 quarters · filed 2025-02-19 | $130.48M derived: sum of 4 quarters · filed 2025-02-19 | |||
| 2023-03-31 | $30.10M 10-Q · filed 2024-05-03 | $59.95M derived: sum of 2 quarters · filed 2025-02-19 | $96.05M derived: sum of 3 quarters · filed 2025-02-19 | $132.24M derived: sum of 4 quarters · filed 2025-02-19 | |||
| 2022-12-31 | $29.85M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $65.94M derived: sum of 2 quarters · filed 2025-02-19 | $102.13M derived: sum of 3 quarters · filed 2025-02-19 | $131.71M 10-K · filed 2025-02-19 | |||
| 2022-09-30 | $36.10M 10-Q · filed 2023-11-03 | $72.28M derived: sum of 2 quarters · filed 2023-11-03 | $101.86M 10-Q · filed 2023-11-03 | $128.80M derived: sum of 4 quarters · filed 2024-02-21 | |||
| 2022-06-30 | $36.19M 10-Q · filed 2023-08-04 | $65.77M 10-Q · filed 2023-08-04 | $92.70M derived: sum of 3 quarters · filed 2024-02-21 | $119.71M derived: sum of 4 quarters · filed 2024-02-21 | |||
| 2022-03-31 | $29.58M 10-Q · filed 2023-05-05 | $56.51M derived: sum of 2 quarters · filed 2024-02-21 | $83.52M derived: sum of 3 quarters · filed 2024-02-21 | $110.62M derived: sum of 4 quarters · filed 2024-02-21 | |||
| 2021-12-31 | $26.94M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $53.94M derived: sum of 2 quarters · filed 2024-02-21 | $81.04M derived: sum of 3 quarters · filed 2024-02-21 | $105.26M 10-K · filed 2024-02-21 | |||
| 2021-09-30 | $27.00M 10-Q · filed 2022-11-03 | $54.10M derived: sum of 2 quarters · filed 2022-11-03 | $78.32M 10-Q · filed 2022-11-03 | $101.05M derived: sum of 4 quarters · filed 2023-02-17 | |||
| 2021-06-30 | $27.10M 10-Q · filed 2022-07-29 | $51.32M 10-Q · filed 2022-07-29 | $74.04M derived: sum of 3 quarters · filed 2023-02-17 | $94.57M derived: sum of 4 quarters · filed 2023-02-17 | |||
| 2021-03-31 | $24.22M 10-Q · filed 2022-05-06 | $46.94M derived: sum of 2 quarters · filed 2023-02-17 | $67.47M derived: sum of 3 quarters · filed 2023-02-17 | $89.90M derived: sum of 4 quarters · filed 2023-02-17 | |||
| 2020-12-31 | $22.72M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | $43.25M derived: sum of 2 quarters · filed 2023-02-17 | $65.68M derived: sum of 3 quarters · filed 2023-02-17 | $85.83M 10-K · filed 2023-02-17 | |||
| 2020-09-30 | $20.53M 10-Q · filed 2021-11-03 | $42.95M derived: sum of 2 quarters · filed 2021-11-03 | $63.11M 10-Q · filed 2021-11-03 | $82.28M derived: sum of 4 quarters · filed 2022-02-15 | |||
| 2020-06-30 | $22.43M 10-Q · filed 2021-08-03 | $42.59M 10-Q · filed 2021-08-03 | $61.76M derived: sum of 3 quarters · filed 2022-02-15 | $81.65M derived: sum of 4 quarters · filed 2022-02-15 | |||
| 2020-03-31 | $20.16M 10-Q · filed 2021-05-05 | $39.33M derived: sum of 2 quarters · filed 2022-02-15 | $59.22M derived: sum of 3 quarters · filed 2022-02-15 | $81.71M derived: sum of 4 quarters · filed 2022-02-15 | |||
| 2019-12-31 | $19.17M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $39.06M derived: sum of 2 quarters · filed 2022-02-15 | $61.55M derived: sum of 3 quarters · filed 2022-02-15 | $82.03M 10-K · filed 2022-02-15 | |||
| 2019-09-30 | $19.89M 10-Q · filed 2020-10-27 | $42.38M derived: sum of 2 quarters · filed 2020-10-27 | $62.85M 10-Q · filed 2020-10-27 | $85.00M derived: sum of 4 quarters · filed 2021-02-12 | |||
| 2019-06-30 | $22.49M 10-Q · filed 2020-07-30 | $42.96M 10-Q · filed 2020-07-30 | $65.10M derived: sum of 3 quarters · filed 2021-02-12 | $85.77M derived: sum of 4 quarters · filed 2021-02-12 | |||
| 2019-03-31 | $20.48M 10-Q · filed 2020-05-07 | $42.61M derived: sum of 2 quarters · filed 2021-02-12 | $63.28M derived: sum of 3 quarters · filed 2021-02-12 | $82.84M derived: sum of 4 quarters · filed 2021-02-12 | |||
| 2018-12-31 | $22.14M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | $42.80M derived: sum of 2 quarters · filed 2021-02-12 | $62.37M derived: sum of 3 quarters · filed 2021-02-12 | $81.17M 10-K · filed 2021-02-12 | |||
| 2018-09-30 | $20.67M 10-Q · filed 2019-11-06 | $40.23M derived: sum of 2 quarters · filed 2019-11-06 | $59.03M 10-Q · filed 2019-11-06 | ||||
| 2018-06-30 | $19.56M 10-Q · filed 2019-08-02 | $38.36M 10-Q · filed 2019-08-02 | |||||
| 2018-03-31 | $18.80M 10-Q · filed 2019-05-07 | ||||||
| 2017-12-31 | $68.01M 10-K · filed 2020-02-14 | ||||||
| 2016-12-31 | $48.31M 10-K · filed 2019-02-20 | ||||||
| 2015-12-31 | $24.88M 10-K · filed 2018-02-21 | ||||||
| 2014-12-31 | $5.39M 10-K · filed 2017-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |